Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
KEYNOTE-495/KEYIMPACT: UPDATED ANALYSIS OF A BIOMARKER-DIRECTED, RANDOMIZED, PHASE 2 TRIAL OF PEMBROLIZUMAB-BASED COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCERopen access
- Authors
- Herbst, R[Herbst, Roy]; Lam, WS[Lam, Wei-Sen]; Hellmann, M[Hellmann, Matthew]; Gubens, M[Gubens, Matthew]; Aggarwal, C[Aggarwal, Charu]; Tan, DSW[Tan, Daniel Shao Weng]; Felip, E[Felip, Enriqueta]; Chiu, J[Chiu, Joanne]; Lee, JS[Lee, Jong-Seok]; Yang, NCH[Yang, Names Chih-Hsin]; Garon, E[Garon, Edward]; Finocchiaro, G[Finocchiaro, Gioyanna]; Ahn, MJ[Ahn, Myung-Ju]; Luft, A[Luft, Alexander]; Landers, G[Landers, Gregory]; Basso, A[Basso, Andrea]; Ma, H[Ma, Hua]; Kobie, J[Kobie, Julie]; Palcza, J[Palcza, John]; Cristescu, R[Cristescu, RaLvan]; Fong, L[Fong, Lawrence]; Snyder, A[Snyder, Alexandra]; Yuan, JD[Yuan, Jianda]; Gutierrez, M[Gutierrez, Martin]
- Issue Date
- Nov-2022
- Publisher
- BMJ PUBLISHING GROUP
- Citation
- JOURNAL FOR IMMUNOTHERAPY OF CANCER, v.10, pp.A666 - A666
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL FOR IMMUNOTHERAPY OF CANCER
- Volume
- 10
- Start Page
- A666
- End Page
- A666
- ISSN
- 2051-1426
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.